Columbia Laboratories to Receive One-time Payment of $300K from Actavis for CRINONE US Manufacturing Rights

Columbia Laboratories (NASDAQ: CBRX ) has entered into an agreement with Actavis (NYSE: ACT ) ("Actavis") for early termination of the companies' current exclusive Supply Agreement for CRINONE® (progesterone gel). The exclusive Supply Agreement, which would have otherwise terminated in May 2015, provided for Columbia to receive